ClinicalTrials.gg
TerminatedNCT06343883Updated Nov 19, 2026Results posted

Investigation of Low-intensity Focused Ultrasound Pressure

An interventional study of low-intensity focused ultrasound - low pressure and low-intensity focused ultrasound - medium pressure in Somatic Pain, sponsored by Virginia Polytechnic Institute and State University. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Basic science

How we know

Why this study was terminated
Not funded.
Updated Nov 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Nociceptive Pain with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Nociceptive Pain · United States.

Enrollment
12th of 12
1 · median 65
Started
2024
with 4 others
No phase
7 of 16
none open now
Registered
15th of 16
by date

Among the 16 studies in Nociceptive Pain with a site in United States, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2024, is one of 7 with no phase, and was the 15th registered.

Nociceptive Pain

97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.

Browse Nociceptive Pain studies →

Open to participants now

2 of the 16 studies in Nociceptive Pain with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Nociceptive Pain studies recruiting now, 5 (42%) set no upper age limit and 4 (33%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Nociceptive Pain with a site in United States, or all of them as a file.
02

Study summary

Investigating the relationship between input pressure of low-intensity focused ultrasound and an evoked potential in both eeg and fMRI.

Read the detailed description

Study aims to determine safety and efficacy of variable pressures of low-intensity focused ultrasound using an electrical stimulation to create a somatosensory evoked potential and record eeg and fMRI outcome measures. A primary safety study will be conducted prior to 'full scale' data collection.

03

Conditions studied

  • Somatic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Understand and speak English

Exclusion criteria

Exclusion Criteria:

  1. Claustrophobia (scanning environment may be uncomfortable).
  2. to MRI: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants.
  3. Contraindications to CT: pregnancy
  4. Active medical disorder or treatment with potential CNS effects (e.g. Alzheimer's)
  5. History of neurologic disorder. (e.g. Parkinson's, Epilepsy, or Essential Tremor)
  6. History of head injury resulting in loss of consciousness for >10 minutes.
  7. History of alcohol or drug dependence (through self-report).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Safety Check - high pressure application

    Small cohort to be collected prior to other study cohorts. Highest of 3 pressures of interest will be applied to the S1 (somatosensory cortex) with a follow-up MRI conducted 24-72 hours post.

    Device: low-intensity focused ultrasound - high pressure

  • Experimental
    EEG

    Electrical stimulation utilized to generate SEPs, performed pre and post LIFU application. One of three LIFU pressures will be applied. One per study visit (3), randomized order. EEG collected throughout visit (outcome measure).

    Device: low-intensity focused ultrasound - low pressure · Device: low-intensity focused ultrasound - medium pressure · Device: low-intensity focused ultrasound - high pressure

  • Experimental
    fMRI

    Electrical stimulation utilized to generate SEPs, performed pre and post LIFU application. One of three LIFU pressures will be applied. One per study visit (3), randomized order. fMRI collected throughout visit (outcome measure).

    Device: low-intensity focused ultrasound - low pressure · Device: low-intensity focused ultrasound - medium pressure · Device: low-intensity focused ultrasound - high pressure

Interventions

  • Devicelow-intensity focused ultrasound - low pressure

    low-intensity focused ultrasound applied to the S1.

  • Devicelow-intensity focused ultrasound - medium pressure

    low-intensity focused ultrasound applied to the S1.

  • Devicelow-intensity focused ultrasound - high pressure

    low-intensity focused ultrasound applied to the S1.

06

What researchers measure

Primary outcomes

  1. Number of Symptoms Reported

    Participants are asked to report their symptoms on a scale (absent, mild, moderate, severe). Symptoms are reported as number of symptoms reported.

    Time frame: 30 minutes after intervention

  2. Number of Imaging Abnormalities Found on Post-Intervention MRI

    Structural MRI collection for cohort one - evaluated by Neuroradiologist for safety considerations. Primarily looking to rule out any evidence of bleeds.

    Time frame: 2 days post - intervention

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneSafety Check - High Pressure Application
Started1
Completed1
Not completed0

Outcome measures

PrimaryNumber of Symptoms Reported

Participants are asked to report their symptoms on a scale (absent, mild, moderate, severe). Symptoms are reported as number of symptoms reported.

Time frame:
30 minutes after intervention
Reported as:
Number · Symptoms
Number of Symptoms Reported
SymptomsSafety Check - High Pressure Application
Number of Mild Symptoms0
Number of Moderate Symptoms0
Number of Severe Symptoms0
PrimaryNumber of Imaging Abnormalities Found on Post-Intervention MRI

Structural MRI collection for cohort one - evaluated by Neuroradiologist for safety considerations. Primarily looking to rule out any evidence of bleeds.

Time frame:
2 days post - intervention
Reported as:
Number · Image abnormalities
Number of Imaging Abnormalities Found on Post-Intervention MRI
Image abnormalitiesSafety Check - High Pressure Application
Number of Imaging Abnormalities Found on Post-Intervention MRI0

Adverse events

Collected over 2 study visits in a 1 week span.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Check - High Pressure Application0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Safety Check - High Pressure Application
<=18 years0
Between 18 and 65 years1
>=65 years0
Age, Continuous
Age, Continuous(years)Safety Check - High Pressure Application
Median24 (24 to 24)
Sex: Female, Male
Sex: Female, Male(Participants)Safety Check - High Pressure Application
Female0
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Check - High Pressure Application
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Safety Check - High Pressure Application
Hispanic or Latino1
Not Hispanic or Latino0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Safety Check - High Pressure Application
United States1
Baseline Report Of Symptoms
Baseline Report Of Symptoms(Symptom count)Safety Check - High Pressure Application
Number0
08

Study locations

1 site
  • Fralin Biomedical Research Institute at VTC
    Roanoke, Virginia 24016, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Oct 2024, 0 months.

Results were first posted in Nov 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2024
First posted
Apr 3, 2024
StartActual
Oct 16, 2024
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedReportNumber of Symptoms QuestionnaireReportedTime frame: pre/post intervention and 1 week post intervention. → 30 minutes after intervention
  • ChangedBefore MRINow Number of Imaging Abnormalities Found on Post-Intervention MRITime frame: pre and post intervention in cohort 1 → 2 days post - intervention
Nov 19, 2026
Documents
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedEEGTime frame: throughout study visits in cohort 2 - approximately 2 hours per visit across 3 study visits (~2 weeks).
  • RemovedfMRITime frame: throughout study visits in cohort 3 - approximately 2 hours per visit across 3 study visits (~2 weeks).
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedReportNumber of Symptoms QuestionnaireReportedTime frame: pre/post intervention and 1 week post intervention. → 30 minutes after intervention
    • ChangedBefore MRINow Number of Imaging Abnormalities Found on Post-Intervention MRITime frame: pre and post intervention in cohort 1 → 2 days post - intervention
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedEEGTime frame: throughout study visits in cohort 2 - approximately 2 hours per visit across 3 study visits (~2 weeks).
    • RemovedfMRITime frame: throughout study visits in cohort 3 - approximately 2 hours per visit across 3 study visits (~2 weeks).
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06343883
Responsible party
Wynn Legon (Assistant Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Apr 3, 2024
Start date
Oct 16, 2024
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion